The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

A new study from Huashan Hospital, Shanghai, provided strong evidence supporting the efficacy and safety of abrocitinib for ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

Researchers described a new skin disease in a male patient with erythroderma, causing 80 percent of his skin to be covered with red, exfoliating skin lesions that itched and burned. After undergoing ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...